Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease
Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease
复制标题
DOI：
10.1016/j.bbmt.2014.08.014
复制
发表时间：
2015-04-01
影响因子：
4.3
通讯作者：
Duffner, Ulrich
中科院分区：
文献类型：
--
作者：
Al-Homsi, Ahmad Samer;Roy, Tara S.;Duffner, Ulrich
环磷酰胺缺乏造血干细胞毒性及其对免疫系统的独特作用，促使一些研究人员探索其预防移植物抗宿主病（GVHD）的潜力。在单倍相合造血干细胞移植中，移植后环磷酰胺与标准预防一起将GVHD的发生率降低至可接受的比率，而不需要T细胞耗竭。在匹配的相关和无关的供体设置，环磷酰胺单独产生了令人鼓舞的结果。特别值得注意的是，慢性移植物抗宿主病的发病率很低。在这里，我们提出了一个审查的作用机制，移植后环磷酰胺的当前理解和总结其用于预防GVHD的临床数据。(C)2015年美国血液和骨髓移植协会。
Cyclophosphamide's lack of hematopoietic stem cell toxicity and its unique effects on the immune system have prompted several investigators to explore its potential for the prevention of graft-versus-host disease (GVHD). In haploidentical hematopoietic stem cell transplants, post-transplant cyclophosphamide together with standard prophylaxis reduces the incidence of GVHD to acceptable rates without the need for T cell depletion. In matched related and unrelated donor settings, cyclophosphamide alone has produced encouraging results. In particular, the low incidence of chronic GVHD is noteworthy. Here, we present a review of the current understanding of the mechanism of action of post-transplant cyclophosphamide and summarize the clinical data on its use for the prevention of GVHD. (C) 2015 American Society for Blood and Marrow Transplantation.